NDA 022527 · Novartis
Gilenya
Fingolimod Hydrochloride · Oral
NovelBreakthrough therapyPriority reviewLast checked: Nov 20, 2026Latest source record: Aug 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Sep 21, 2010
Approved uses
3
Original approval plus efficacy supplements
Registered trials
92
31 Phase 3, 4 recruiting
FAERS reports
81,755
40,666 serious, 1,120 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 22, 2026.
GILENYA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. GILENYA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. ( 1 )
Mechanism: Fingolimod is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor modulator, and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which fingolimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 11, 2018 Supplement 24 · Efficacy · priority review Breakthrough therapyLabelLetterPediatric CDTL Review
- Jul 20, 2011 Supplement 2 · Efficacy LetterLabel
- Sep 21, 2010 Original approval · Type 1 - New Molecular Entity · priority review NovelOther Important Information from FDASummary ReviewPediatric Written Request
2 products under this application
- GILENYA · FINGOLIMOD HYDROCHLORIDE EQ 0.5MG BASE · CAPSULE, ORAL · Prescription · TE AB
- GILENYA · FINGOLIMOD HYDROCHLORIDE EQ 0.25MG BASE · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Fingolimod" as an intervention, any sponsor and status, largest first.
- STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)Completed
Novartis PharmaceuticalsNovartis (NVS)
NCT01585298 · 6,998 participants · Start Apr 29, 2012 · Primary completion Dec 12, 2016
Drug: FTY720 · For: Multiple Sclerosis
Sites: Ostfildern, Germany; Munich, Germany; Altenholz-Stift, Germany · 258 sites in all
- Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple SclerosisPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01201356 · 4,125 participants · Start Sep 13, 2010 · Primary completion Oct 19, 2018
Drug: Fingolimod · For: Relapsing Forms of Multiple Sclerosis
Sites: Cullman, Alabama; Oceanside, California; Sacramento, California · 458 sites in all
- Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) PatientsPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT01127750 · 2,417 participants · Start May 2010 · Primary completion Oct 2011
Drug: FTY720 · For: Relapsing Multiple Sclerosis
Sites: Box Hill, Australia; Heidelberg, Australia; Kogarah, Australia · 289 sites in all
- Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension PhasePivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00340834 · 1,292 participants · Start May 2006 · Primary completion Jul 2011
Drug: Fingolimod 1.25 mg; Fingolimod 0.5 mg and 1 more · For: Multiple Sclerosis
Sites: Cullman, Alabama; Phoenix, Arizona; Oceanside, California · 170 sites in all
- Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple SclerosisPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00289978 · 1,272 participants · Start Jan 2006 · Primary completion Jul 2009
Drug: Fingolimod 1.25 mg; Fingolimod 0.5 mg and 1 more · For: Relapsing-remitting Multiple Sclerosis
Sites: Woodville South, Australia; Burrabil Avenue, Suite 17, Gosford, Australia; Chatswood, Australia · 115 sites in all
- Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00355134 · 1,083 participants · Start Jun 2006 · Primary completion Jun 2011
Drug: Fingolimod; Placebo · For: Multiple Sclerosis
Sites: Birmingham, Alabama; Cullman, Alabama; Mobile, Alabama · 112 sites in all
- MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus CopaxonePivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT01633112 · 1,064 participants · Start Aug 9, 2012 · Primary completion Apr 30, 2018
Drug: fingolimod; glatiramer acetate · For: Relapsing-remitting Multiple Sclerosis (RRMS)
Sites: Cullman, Alabama; Phoenix, Arizona; Tucson, Arizona · 130 sites in all
- A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple SclerosisPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01216072 · 1,053 participants · Start Aug 2010 · Primary completion Aug 2012
Drug: Fingolimod; Standard MS DMTs · For: Relapsing Forms of Multiple Sclerosis
Sites: Birmingham, Alabama; Cullman, Alabama; Phoenix, Arizona · 149 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue10,604
- multiple sclerosis relapse7,266
- headache7,128
- dizziness5,278
- white blood cell count decreased3,936
- gait disturbance3,747
- hypoaesthesia3,669
- fall3,422
- lymphocyte count decreased3,407
- nausea3,362
- malaise3,069
- memory impairment2,942
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2010 | 13 |
| 2011 | 2,683 |
| 2012 | 4,662 |
| 2013 | 4,226 |
| 2014 | 3,074 |
| 2015 | 8,196 |
| 2016 | 10,022 |
| 2017 | 10,260 |
| 2018 | 11,493 |
| 2019 | 11,029 |
| 2020 | 6,536 |
| 2021 | 3,850 |
| 2022 | 2,992 |
| 2023 | 1,440 |
| 2024 | 670 |
| 2025 | 411 |
| 2026 | 197 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Gilenya (Fingolimod HCl)
2024 spending
$53.7M
Beneficiaries
839
4,535 claims
Per beneficiary
$63,964
$337.02 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $449,518,264 |
| 2021 | $408,502,681 |
| 2022 | $363,110,730 |
| 2023 | $125,490,483 |
| 2024 | $53,665,922 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis.
Rindi LV, Zaçe D, Braccialarghe N, et al. · Drug Saf 2024 · Systematic Review, Meta-Analysis
- Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Tramacere I, Virgili G, Perduca V, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- The effect of Fingolimod on patients with moderate to severe COVID-19.
Teymouri S, Pourbayram Kaleybar S, Hejazian SS, et al. · Pharmacol Res Perspect 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- MS Fatigue Post High-Efficacy Treatment.
Sales C, Patel R, Wijeratne T, et al. · Eur J Neurol 2025 · Meta-Analysis, Systematic Review
- Comparative effectiveness of disease-modifying therapies for highly active relapsing-remitting multiple sclerosis despite previous treatment - a systematic review and network meta-analysis.
Köhler M, Paul F, Janke K, et al. · BMC Neurol 2025 · Comparative Study, Network Meta-Analysis
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.